Pharmacogenetics of drug-metabolizing enzymes: The prodrug hypothesis

Pharmacogenomics

Volumn 13, Issue 1, 2012, Pages 83-89

  Begg, Evan J ^a   Helsby, Nuala A ^b   Jensen, Berit P ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Drug metabolism; Individualized dosing; Pharmacogenetics; Prodrug

Indexed keywords

ATOMOXETINE; AZATHIOPRINE; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DRUG METABOLIZING ENZYME; FLUOROURACIL; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; MERCAPTOPURINE; PERHEXILINE; PHENYTOIN; PROTON PUMP INHIBITOR; SUXAMETHONIUM; TAMOXIFEN; TETRABENAZINE; THIOPURINE METHYLTRANSFERASE; WARFARIN;

BREAST CANCER; CROHN DISEASE; CYP2C19 GENE; CYP2C9 GENE; CYP2D6 GENE; DIARRHEA; DRUG LABELING; DRUG METABOLISM; ENZYME ACTIVITY; FOOD AND DRUG ADMINISTRATION; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HUMAN; NEUTROPENIA; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHENOTYPE; REVIEW; TPMT GENE; UGT1A1 GENE; VKORC1 GENE;

ARYL HYDROCARBON HYDROXYLASES; AZATHIOPRINE; CAMPTOTHECIN; CYTOCHROME P-450 CYP2D6; ENZYMES; GLUCURONOSYLTRANSFERASE; HUMANS; METABOLIC DETOXICATION, DRUG; METHYLTRANSFERASES; MIXED FUNCTION OXYGENASES; PRODRUGS; TAMOXIFEN; TICLOPIDINE; WARFARIN;

EID: 83755183490     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.134     Document Type: Review

References (25)

1. Laing RE, Hess P, Shen Y, Wang J, Hu SX. The role and impact of SNPs in pharmacogenetics and personalized medicine. Curr. Drug Metab. 12, 460-486 (2011).
2. Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolising enzymes, and clinical practice. Pharmacol. Rev. 58, 521-590 (2006). (Pubitemid 44403684)
3. Flockhart DA, Skaar T, Berlin DS, Klein TE, Nguyen AT. Clinically available pharmacogenomics tests. Clin. Pharmacol. Ther. 86, 109-113 (2009).
4. Becquemont L, Alfirevic A, Amstutz U et al. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB conference on pharmacogenetics and pharmacogenomics. Pharmacogenomics 12, 113-124 (2010).
5. Canterbury District Health Board. Preferred Medicines List, 15th Edition. The Caxton Press, Christchurch, New Zealand. ISBN 0-473-08171-7 (2011).
6. Zhou S. Clinical pharmacogenomics of thiopurine S methyltransferase. Curr. Clin. Pharmacol. 1, 119-28 (2006).
7. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 32, 651-662 (1980). (Pubitemid 10061685)
8. Roberts RL, Gearry RB, Kennedy MA, Barclay ML. Beyond TPMY: genetic influences on thiopurine drug responses in inflammatory bowel disease. Per. Med. 5(3), 233-248 (2008). (Pubitemid 351819081)
9. Kaskas BA, Louis E, Hindorf U et al. Safe treatment of thiopurine S methyltransferase deficient Crohn's disease patients with azathioprine. Gut 52, 140-142 (2003). (Pubitemid 36020781)
10. Gardiner SJ, Gearry RB, Begg EJ, Zhang M, Barclay ML. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold. Clin. Gastroenterol. Hepatol. 6, 654-660 (2008).
11. Gardiner SJ, Begg EJ. Pharmacogenetics testing for drug metabolizing enzymes - is it happening in practice? Pharmacogenet. Genomics 15, 365-369 (2005). (Pubitemid 40676559)
12. Schroth W, Goetz MP, Hamann U et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302 (13), 1429-1436 (2009).
13. Mega JL, Simon T, Collet JP et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI. JAMA 304(16), 1821-1830 (2010).
14. Bouman HJ, Schomig E, van Werkum JW et al. Paraoxonase 1 is a major determinant of clopidogrel efficacy. Nat. Med. 17, 110-116 (2011).
15. Marsh S, Hoskins LM. Irinotecan pharmacogenomics. Pharmacogenomics 11(7), 1003-1010 (2010).
16. Pirmohamed M. Warfarin: almost 60 years old and still causing problems. Br. J. Clin. Pharmacol. 62(5), 509-511 (2006). (Pubitemid 44571571)
17. The International Warfarin Pharmacogenomics Consortium; Klein TE, Altman RB et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360, 753-764 (2009).
18. Marsh S. Thymidylate synthase pharmacogenetics. Invest. New Drugs 23(6), 533-537 (2005). (Pubitemid 43162472)
19. Thorn CF, Marsh S, Carrillo MW, McLeod HL, Klein TE, Altman RB. PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet. Genomics 21, 237-242 (2011).
20. Helsby NA, Hui CY, Goldthorpe MA et al. The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation. Br. J. Clin. Pharmacol. 70, 844-53 (2010).
21. Ramanaiah TV, Gajanana A. Superior antimalarial activity of proguanil to cycloguanil after in vitro bioconversion. Trans. R. Soc. Trop. Med. Hyg. 82, 358-359 (1988).
22. Herrlin K, Massele AY, Rimoy G et al. Slow chlorguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotype. Clin. Pharmacol. Ther. 68, 189-198 (2000). (Pubitemid 30659174)
23. Mallal S, Phillips E, Carosi G et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358, 568-579 (2008).
24. Dalen P, Dahl ML, Bernal Ruiz ML, Nordin J, Bertilsson L. 10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin. Pharmacol. Ther. 63, 444-452 (1998). (Pubitemid 28214968)
25. Stamp L, Roberts R, Kennedy M, Barclay M, O'Donnell J, Chapman P. The use of low dose methotrexate in rheumatoid arthritis - are we entering a new era of therapeutic drug monitoring and pharmacogenomics? Biomed. Pharmacother. 10, 678-87 (2006). (Pubitemid 44821708)